A study of the impact of Gliadel for initial and recurrent malignant glioma on the nerve fibers Phase 2 study

A study of the impact of Gliadel for initial and recurrent malignant glioma on the nerve fibers Phase 2 study - A study of impact of Gliadel on the nerve fibers

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019160

Enrollment

Registered

2015-10-01

Start date

2015-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Initial and recurrent malignant glioma

Interventions

Gliadel implantation Primary malignant glioma Chemoradiation therapy (Radiation temodal) Chemotherapy (temodal) Recurrent malignant glioma Chemotherapy (temodal)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: There is a suspicion of a malignant glioma in the brain parenchyma It thought possible corticospinal truct sparing

Exclusion criteria

Exclusion criteria: Patient it is determined that there is likely to die within 6 months Patients who have a history or complications of malignant tumors other than brain Patient pregnancy, is a breast-feeding women

Design outcomes

Primary

Measure	Time frame
Measurement of three-dimensional distance from the cutting surface to the corticospinal tract. Motor function evaluation of the upper and lower extremities, next day, 4weeks and 12 weeks after operation by Manual Muscle Testing.	—

Countries

Japan

Contacts

Public ContactRyogo Anei

Asahikawa Medical University Neurosurgery

ryogoanei@gmail.com0166-65-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026